The use of a vascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease.
To report the results of intravitreal use of ranibizumab in a patient with macular edema due to Eales disease. This was an open-label, Phase 1, 6-month study of the safety and efficacy of intravitreally administered ranibizumab in patients with macular edema due to Eales disease. A single patient was eligible for the study during the 2 years of recruitment. She received 3 monthly intravitreal injections of 0.5 mg of ranibizumab for 3 months. At each of her monthly visits during the 6-month study, she was evaluated with a full ocular examination and optical coherence tomography imaging of the macula. Primary outcome measure was change in optical coherence tomography central subfield thickness at 6 months. The central macular thickness as measured on optical coherence tomography reduced from 269 μm at baseline to 186 μm at 3 months. This reduction was transient with subsequent increase to 262 μm at the conclusion of the study at 6 months. Ranibizumab use led to transient resolution of macular edema at 3 months; however, this reduction in edema was not sustained.